Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fennec Pharmaceuticals (FENC) Non Operating Income (2016 - 2025)

Historic Non Operating Income for Fennec Pharmaceuticals (FENC) over the last 15 years, with Q3 2025 value amounting to -$449000.0.

  • Fennec Pharmaceuticals' Non Operating Income rose 1575.98% to -$449000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.9 million, marking a year-over-year increase of 3212.64%. This contributed to the annual value of -$2.6 million for FY2024, which is 1939.52% up from last year.
  • According to the latest figures from Q3 2025, Fennec Pharmaceuticals' Non Operating Income is -$449000.0, which was up 1575.98% from -$420000.0 recorded in Q2 2025.
  • Fennec Pharmaceuticals' 5-year Non Operating Income high stood at $190000.0 for Q1 2021, and its period low was -$1.2 million during Q4 2022.
  • For the 5-year period, Fennec Pharmaceuticals' Non Operating Income averaged around -$481500.0, with its median value being -$481500.0 (2024).
  • In the last 5 years, Fennec Pharmaceuticals' Non Operating Income soared by 201111.11% in 2021 and then crashed by 148333.33% in 2022.
  • Quarter analysis of 5 years shows Fennec Pharmaceuticals' Non Operating Income stood at -$12000.0 in 2021, then crashed by 10083.33% to -$1.2 million in 2022, then grew by 29.3% to -$864000.0 in 2023, then increased by 20.6% to -$686000.0 in 2024, then skyrocketed by 34.55% to -$449000.0 in 2025.
  • Its Non Operating Income was -$449000.0 in Q3 2025, compared to -$420000.0 in Q2 2025 and -$357000.0 in Q1 2025.